Inspiration Healthcare (IHC) AI Stock Analysis

• Market Cap: £21.70M
• Dividend Yield: N/A
• Average Volume (3M): 40.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 31.78%
• EPS Growth: 10.27%
• Country: UK
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 89,663,370
• 10 Day Avg. Volume: 75,140
• 30 Day Avg. Volume: 40,346
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.27
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): £40.50M

• Rating: 52 Neutral
• Price Target: 27.00 p ▲(83.05% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is primarily held back by weak financial performance, including worsening losses, reduced margins, rising leverage, and negative operating/free cash flow. Technicals are a partial offset with strong trend and MACD, but overbought RSI/Stoch readings add near-term risk. Valuation is constrained by a negative P/E, consistent with ongoing unprofitability.

Positive Factors

Niche clinical focus

A specialized focus on neonatal and respiratory acute-care devices creates durable clinical differentiation. Hospitals and NICUs value proven, specialized equipment, which supports long procurement cycles, installed-base durability and higher switching costs versus generalist suppliers.

Diversified revenue mix with recurring consumables

A blended model of device sales, recurring consumables, third-party distribution and services provides stable, repeatable revenue streams. Consumables tied to installed devices and distribution margins smooth revenue volatility and underpin long-term cash flow potential if the installed base grows.

Recent top-line growth

Material revenue growth (~32%) signals sustained commercial traction and stronger market demand over recent periods. Durable top-line expansion can increase installed base, lift recurring consumables and enable better fixed-cost absorption, supporting structural margin recovery if sustained.

Negative Factors

Worsening profitability and margins

Declining gross margins and rising net losses indicate structural margin pressure or unfavorable product mix. Persistent negative EBIT/EBITDA reduces reinvestment capacity, weakens pricing power or cost control, and makes sustained profitability recovery harder absent business-model improvements.

Negative operating and free cash flow

Negative operating and free cash flow point to strained cash generation and operational inefficiency. Over time this forces reliance on external funding, raises financing costs, and limits capital for R&D, inventory build or sales expansion—constraining durable growth execution.

Weakened balance sheet and rising leverage

A sharply reduced equity base and higher leverage materially reduce financial flexibility. Elevated debt-to-equity increases refinancing and covenant risk, limits ability to pursue tenders or inventory build-outs, and raises vulnerability to procurement timing or reimbursement shifts.

Inspiration Healthcare Business Overview & Revenue Model

Company Description

Inspiration Healthcare Group plc, together with its subsidiaries, supplies medical technology for critical care, operating theatre, and home healthcare applications worldwide. The company provides neonatal intensive care products, such as inspiration air/oxygen blenders; Tecotherm Neo, a servo control device for total body cooling and warming to monitor the infant's temperature for every 2 seconds and making minute changes to the cooling fluid to ensure that the infant's temperature remains stable; LifeStart, a neonatal bedside resuscitation unit; and Inspire rPAP, a 2-piece non-invasive system for the initial stabilization and resuscitation of infants. It also offers adult intensive care products; AlphaCore5, a patient warming system for the prevention of inadvertent hypothermia; and CosyTherm2, a patient warming system for the management of body temperature in neonates. In addition, the company provides respiratory disposables and thermo-regulating products for babies. Further, it is involved in the distribution of third party products, including infusion therapy products for parenteral feeding and chemotherapy applications; and provision of technology support services and spare parts. Inspiration Healthcare Group plc was incorporated in 1998 and is headquartered in Crawley, the United Kingdom.

How the Company Makes Money

Inspiration Healthcare generates revenue primarily through the sale of its medical devices and equipment to hospitals, healthcare providers, and distributors. Key revenue streams include direct sales of respiratory support devices, patient monitoring systems, and accessories, as well as ongoing maintenance and servicing contracts. The company also benefits from partnerships with healthcare institutions and distributors that help expand its market reach and enhance product availability. Additionally, IHC may engage in research and development collaborations that can lead to new product innovations, further contributing to its earnings.

Inspiration Healthcare Financial Statement Overview

Summary

Overall financials indicate pressure across profitability, leverage, and cash generation. Net losses have increased, gross margin fell to 42.82% (from 47.55%), leverage rose (debt-to-equity 0.90) alongside a sharp drop in equity, and 2025 operating/free cash flow were negative—raising liquidity and execution risk.

Income Statement

Inspiration Healthcare's income statement shows a decline in profitability, with net losses increasing over the past two years. Gross profit margin decreased to 42.82% in 2025 from 47.55% in 2024. Revenue growth has been inconsistent, with a slight increase in 2025 compared to a decrease in 2024. The company is facing significant challenges in maintaining profitability, as evidenced by negative EBIT and EBITDA margins in recent years.

Balance Sheet

The balance sheet reveals a weakening equity position, with stockholders' equity nearly halving from 2024 to 2025. The debt-to-equity ratio increased to 0.90 in 2025, indicating rising leverage. The equity ratio also decreased, showing reduced financial stability. This suggests potential financial risk despite a stable asset base.

Cash Flow

Cash flow analysis indicates deteriorating cash management, with negative operating and free cash flows in 2025. The free cash flow to net income ratio is negative, pointing to challenges in generating cash relative to earnings. The operating cash flow to net income ratio also reflects struggling operations, with significant cash outflows.

Breakdown	TTM	Jan 2024	Jan 2023	Jan 2022	Jan 2021	Jan 2020
Income Statement
Total Revenue	45.20M	38.25M	37.63M	41.23M	41.05M	36.98M
Gross Profit	20.06M	16.38M	17.89M	17.63M	20.25M	17.14M
EBITDA	-9.09M	-12.44M	-2.43M	2.76M	6.17M	4.47M
Net Income	-11.44M	-14.97M	-6.03M	272.00K	4.23M	2.81M
Balance Sheet
Total Assets	36.71M	41.08M	49.01M	54.89M	50.11M	43.23M
Cash, Cash Equivalents and Short-Term Investments	620.00K	733.00K	609.00K	2.28M	9.25M	10.65M
Total Debt	12.91M	14.97M	12.83M	13.08M	7.54M	3.17M
Total Liabilities	20.34M	24.45M	20.05M	19.42M	14.62M	11.66M
Stockholders Equity	16.37M	16.64M	28.97M	35.47M	35.49M	31.58M
Cash Flow
Free Cash Flow	3.05M	-3.52M	380.00K	-11.86M	-436.00K	3.79M
Operating Cash Flow	3.62M	-1.55M	2.01M	-3.52M	3.54M	4.71M
Investing Cash Flow	-2.63M	-1.74M	-2.69M	-8.34M	-3.97M	-14.06M
Financing Cash Flow	-2.88M	3.61M	-1.19M	4.88M	-964.00K	15.53M

Inspiration Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IHC, the sentiment is Positive. The current price of 14.75 is below the 20-day moving average (MA) of 23.65, below the 50-day MA of 18.73, and below the 200-day MA of 20.24, indicating a bullish trend. The MACD of 1.78 indicates Positive momentum. The RSI at 62.61 is Neutral, neither overbought nor oversold. The STOCH value of 36.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:IHC.

Inspiration Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	74 Outperform	£188.13M	12.60	23.64%	3.48%	10.80%	1.75%
SN	70 Outperform	£10.63B	22.64	9.30%	2.35%	2.51%	56.56%
AMS	69 Neutral	£425.86M	19.10	3.69%	1.25%	68.03%	-18.27%
CTEC	67 Neutral	£4.55B	37.08	10.53%	2.11%	4.18%	37.65%
IHC	52 Neutral	£21.70M	-18.39	-69.35%	―	31.78%	10.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SUN	43 Neutral	£4.20M	77.73	-16.78%	―	-4.98%	-114.29%

Inspiration Healthcare Corporate Events

Inspiration Healthcare Wins Four-Year NHS Neonatal Ventilator Framework

Inspiration Healthcare has secured re-appointment to the NHS Supply Chain framework as an approved supplier of neonatal respiratory care equipment for England and Wales for a further four years. The company has also been ranked the number one neonatal ventilator supplier within this framework for the 2025/26 period, cementing its leadership in this specialist market.

The renewed framework agreement gives the Group enhanced medium-term revenue visibility in its core UK market and supports sales of capital equipment, consumables and associated service contracts. It also streamlines procurement for NHS Trusts and strengthens Inspiration Healthcare’s competitive positioning ahead of future tender cycles, underpinning its strategy to grow market share and long-term shareholder value.

The most recent analyst rating on (GB:IHC) stock is a Hold with a £23.50 price target. To see the full list of analyst forecasts on Inspiration Healthcare stock, see the GB:IHC Stock Forecast page.

Inspiration Healthcare lifts revenue 24% and secures major US ventilator deal

Inspiration Healthcare Group reported a strong FY26 performance, with revenue rising 24% to £47.5 million, slightly above market expectations, driven by a robust second half and improved execution under its “Back to Basics” strategy. Adjusted EBITDA is expected to meet consensus, while tighter working capital management helped cut net debt by 39% to £5.1 million over the year.

The Group’s SLE neonatal ventilation unit outperformed management expectations in the second half, supported by new distributor managers in Southeast Asia and Latin America to rebuild its international presence. Inspiration also signed a three-year purchasing deal in the US via its Airon subsidiary, including an initial 150-unit ventilator order and ongoing consumables and service income, underpinning ambitions to double Airon revenue and strengthen higher-quality, recurring revenue streams.

Management said its refreshed structure around three business units—SLE, Inspiration Healthcare as a UK and Ireland medtech channel, and Airon in pneumatic ventilation—has restored international growth momentum. A solid sales pipeline and continued focus on Europe and recurring revenues leave the company entering FY27 with growing confidence and an enhanced competitive position in neonatal intensive care.

The most recent analyst rating on (GB:IHC) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on Inspiration Healthcare stock, see the GB:IHC Stock Forecast page.

Inspiration Healthcare Appoints Cavendish as Joint Broker to Bolster Market Support

Inspiration Healthcare Group has appointed Cavendish Capital Markets Limited as a joint broker with immediate effect, working alongside its existing nominated adviser and corporate broker Panmure Liberum. The move is expected to strengthen the AIM-quoted company’s capital markets support and investor reach as it continues to expand its presence in the global neonatal intensive care and medical technology markets.

The most recent analyst rating on (GB:IHC) stock is a Hold with a £15.00 price target. To see the full list of analyst forecasts on Inspiration Healthcare stock, see the GB:IHC Stock Forecast page.

Inspiration Healthcare’s Airon Wins Major Three-Year US Ventilator Deal

Inspiration Healthcare’s US subsidiary, Airon Corporation, has signed a three-year purchasing agreement with a major US healthcare provider, securing an initial order for 150 of its Model A and Neo ventilators and related accessories. The deal marks a significant expansion of Airon’s installed base in the US and creates a new long-term, high-quality revenue stream, including recurring consumables and service income, directly underpinning Inspiration Healthcare’s strategy to double Airon’s revenue within five years and strengthening the group’s ambitions and competitive positioning in the US market.

The most recent analyst rating on (GB:IHC) stock is a Sell with a £11.00 price target. To see the full list of analyst forecasts on Inspiration Healthcare stock, see the GB:IHC Stock Forecast page.